Ozon Pharmaceuticals reported for 2025 under RAS

Ozon Pharmaceuticals' net profit under RAS for 2025 amounted to ₽2.35 billion, up 6.8% from ₽2.2 billion in the previous year. Revenue increased by 17.1% to ₽3.42 billion against ₽2.92 billion a year earlier.